NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
Akeso
Jiangsu Cancer Institute & Hospital
Qilu Pharmaceutical Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
TYK Medicines, Inc
EQRx International, Inc.
Istituto Clinico Humanitas
Tongji Hospital
Shenzhen People's Hospital
HiberCell, Inc.